Infant Bacterial Therapeutics (IBT) Q2 2026 earnings summary

Executive summary

• Continued focus on bringing IBP-9414, a live biotherapeutic for premature infants, to market, with regulatory and manufacturing milestones progressing in both the EU and US.

• IBP-9414 demonstrated a 27% reduction in all-cause mortality in preterm infants in Phase III, with significant regulatory designations received.

• No revenue generated; operations remain pre-commercial, with ongoing R&D and regulatory expenses.

Financial highlights

• Net sales were SEK 0 for both Q2 and H1 2026, unchanged from prior periods.

• Operating loss for Q2 2026 was SEK -30.1 million (vs. -20.1 million Q2 2025); H1 2026 operating loss was SEK -53.6 million (vs. -37.6 million H1 2025).

• Result after tax for H1 2026 was SEK -52.7 million (vs. -35.9 million H1 2025).

• Cash flow for H1 2026 was SEK -35.6 million (vs. -43.9 million H1 2025); cash balance at June 30, 2026 was SEK 108.6 million.

• Equity per share at June 30, 2026 was SEK 3.94 (vs. 9.97 June 30, 2025); equity ratio was 44% (vs. 70%).

Outlook and guidance

• Goal remains to submit the Biologics License Application (BLA) for IBP-9414 in the US by year-end 2026.

• Capital is considered sufficient until market approval is obtained.